SRC
NVCR icon

Shufro Rose & Co’s NovoCure NVCR Stock Holding History

Shufro Rose & Co’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000
Closed -$132K – 312
2021
Q1 		$132K Sell
1,000
-300
-23% -$47.5K 0.01% 278
2020
Q4 		$225K Buy
1,300
+300
+30% +$41.1K 0.02% 238
2020
Q3 		$111K Buy
+1,000
New +$80K 0.01% 261
2020
Q1 		– Sell
-2,500
Closed -$210K – 313
2019
Q4 		$210K Sell
2,500
-1,100
-31% -$88.8K 0.02% 273
2019
Q3 		$270K Buy
+3,600
New +$288K 0.03% 240

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Shufro Rose & Co's NVCR Position: Q3 2021 in Review

Shufro Rose & Co sold out of NovoCure (NVCR) in Q3 2021, closing a stake of 1,300 shares — an estimated $288K sold.

Shufro Rose & Co first reported a position in NVCR in Q3 2019 and held it in 7 quarters. The position peaked at $346K in Q4 2020. 317 funds tracked by Wall St. Rank hold NVCR as of Q3 2021.

  • Shufro Rose & Co reported no remaining NovoCure position as of Q3 2021 after selling out during the quarter.
  • Shufro Rose & Co sold 1,300 NovoCure shares in Q3 2021, an estimated $288K.
  • Shufro Rose & Co first reported a position in NovoCure in Q3 2019 and held it in 7 quarters.
  • Shufro Rose & Co's NovoCure position peaked at $346K in Q4 2020.
  • 317 funds tracked by Wall St. Rank held NovoCure as of Q3 2021.

Based on Shufro Rose & Co's 13F filing for Q3 2021, filed 5 Nov 2021.